Mixed Results in NSCLC, SCLC Trials (CME/CE)

(MedPage Today) -- Two-thirds of patients with recurrent, mutated non-small cell lung cancer responded to an investigational agent that selectively targets mutant cells and spares normal ones, results of a preliminary trial showed.
Source: MedPage Today Geriatrics - Category: Geriatrics Source Type: news